Connect
MJA
MJA

Human papillomavirus vaccination and cervical cancer screening by socioeconomic status, Victoria

Bianca Barbaro, Julia M L Brotherton and Dorota M Gertig
Med J Aust 2012; 196 (7): 445. || doi: 10.5694/mja11.11360
Published online: 16 April 2012

To the Editor: From 2007 to 2009 in Australia, a three-dose course of quadrivalent human papillomavirus (HPV) vaccine was offered to all females aged 12–26 years through school and primary health care settings, with coverage recorded on the National HPV Vaccination Program Register (NHVPR).

  • Bianca Barbaro1
  • Julia M L Brotherton2
  • Dorota M Gertig2

  • 1 Public Health Information Development Unit, University of Adelaide, Adelaide, SA.
  • 2 Victorian Cytology Service, Melbourne, VIC.


Acknowledgements: 

We thank Genevieve Chappell for provision of, and advice on, NHVPR data. The NHVPR is funded by the Australian Government. The Victorian Cervical Cytology Registry is funded by the Victorian Government. The NHVPR and Victorian Cervical Cytology Registry are operated by the Victorian Cytology Service.

Competing interests:

Julia Brotherton and Dorota Gertig are investigators on an Australian Research Council Linkage Grant, for which CSL Biotherapies is a partner organisation. Julia Brotherton was an investigator on a national HPV prevalence study (2005–2008) that received funding from CSL Biotherapies and GlaxoSmithKline.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.